Best Health Insurance for Cancer Patients: Denial Rates by Insurer (2026)" class="auto-link">Denial Rates Compared

A cancer diagnosis puts enough stress on patients and families. A health insurance denial on top of that can feel catastrophic. Unfortunately, oncology claims are among the most frequently denied in American health insurance — and the reasons are rarely simple. Understanding which insurers deny cancer-related claims most aggressively, and why, helps patients and caregivers plan for the fight ahead.

Why Cancer Claims Get Denied So Often

Cancer treatment involves a combination of factors that trigger insurer scrutiny:

High cost: Chemotherapy, immunotherapy, targeted therapy, and radiation are extraordinarily expensive. Insurers apply the most intensive utilization management to high-cost services, which means cancer claims face more frequent Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization requirements, step therapy protocols, and medical necessity reviews.

Novel treatments: Oncology moves fast. New immunotherapies, targeted therapies, and CAR-T cell treatments are often denied as "experimental or investigational" even when they carry FDA approval and have become standard of care. Insurers' clinical criteria frequently lag behind medical practice.

Off-label medications: Many FDA-approved cancer drugs are used off-label for specific cancer types where they're the most effective available treatment. Off-label use is a frequent denial trigger, even when supported by clinical evidence and oncologist recommendation.

Clinical trial coverage: Some insurers deny coverage for routine care costs incurred during clinical trial participation. Federal law generally requires ACA plans to cover routine costs, but implementation is inconsistent.

How Major Insurers Compare on Oncology Denials

UnitedHealthcare has faced significant criticism for its oncology prior authorization practices. The insurer requires prior authorization for a wide range of cancer treatments and has drawn state regulatory attention for delays in oncology authorizations. UHC's Medicare Advantage plans have been particularly scrutinized for denying post-hospitalization care for cancer patients.

Cigna has been involved in litigation and regulatory action related to specialty oncology medication coverage, particularly for biologics and targeted therapies. Cigna's proprietary clinical criteria for oncology are not always publicly available, which complicates appeals.

Anthem/Elevance operates differently in different states under different brand names. In states where Anthem administers Blue Cross Blue Shield plans, oncology coverage has generally been stronger due to BCBS's national treatment pathways. However, Anthem's narrowing of specialty oncology networks has created access issues for patients at comprehensive cancer centers.

Aetna has faced class-action litigation related to coverage of cancer genomic testing, with patients alleging that Aetna systematically denied coverage for tumor profiling tests that their oncologists considered medically necessary.

Kaiser Permanente (where available) is consistently rated more highly by oncology patients for integrated care, but its closed-network structure means patients who want care at specialized cancer centers outside Kaiser may face complete denial.

What to Look for When Choosing Insurance as a Cancer Patient

If you're choosing or changing insurance while managing a cancer diagnosis:

Comprehensive cancer center access: Check whether your preferred cancer center (an NCI-designated comprehensive cancer center, for example) is in-network. This single factor may matter more than anything else.

Specialty pharmacy formulary: Review whether the specific medications your oncologist uses are on the formulary and at what cost-sharing tier. Tier 4 and tier 5 specialty drugs can involve thousands of dollars in cost-sharing even with insurance.

Prior authorization burden: Ask the insurer or review plan documents for the list of cancer treatments requiring prior authorization. A shorter list means fewer delays and denials.

External appeal rights: For ACA plans, external appeal rights are standardized. For employer plans (ERISA), check whether the plan allows External Independent Review: Complete Guide" class="auto-link">external review — self-funded plans may not be required to offer it under state law.

Appealing a Cancer Claim Denial

Cancer denials respond particularly well to a specific appeal strategy:

1. Get your oncologist directly involved. A treating oncologist's letter explaining why a specific treatment is the standard of care — and why alternatives are inappropriate — is the most powerful evidence in a cancer appeal.

2. Reference NCCN guidelines. The National Comprehensive Cancer Network publishes clinical practice guidelines that are widely recognized as the standard of care. If your treatment is consistent with NCCN guidelines, say so explicitly.

3. Challenge "experimental" designations. If your treatment is FDA-approved and appears in NCCN guidelines, an insurer calling it "experimental" is on very weak ground. Cite the approval date and indication.

4. Request expedited appeal for urgent situations. Cancer patients often qualify for expedited appeal timelines (72 hours) when waiting for standard appeal timelines would jeopardize health.

Fight Back With ClaimBack

No cancer patient should have to fight their insurer alone while fighting their disease. ClaimBack helps you build a structured, evidence-backed appeal designed to address the specific reasons your claim was denied. Start your appeal at https://claimback.app/appeal.

Related Reading

• What Is Medical Necessity?
• How to Write an Insurance Appeal Letter
• Common Reasons Insurance Claims Are Denied